Biogen Says Its US Manufacturing Will Limit Tariff Impacts (2)

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US.

CEO Chris Viehbacher told analysts that “even if the exemption for pharmaceuticals were to be removed,” Biogen doesn’t expect a material impact from US tariffs this year. He added that the company’s guidance includes possible retaliatory tariffs from China.

The company’s shares rose 0.3% at 9:44 a.m. in New York on Thursday. They’d dropped 21% so far this year through Wednesday’s close.

Biogen’s $2.4 billion in first quarter sales beat Wall Street’s ...